Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927144 · ClinicalTrials.gov registry record · Phase 4
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
A Phase 4 study of Episodic Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 621
- Enrollment target
- 20
- Study locations
NCT03927144: Completed Phase 4 study of Episodic Migraine, sponsored by Amgen.
NCT03927144 is a Phase 4 study of Episodic Migraine that has completed, run by Amgen. The registered enrollment target is 621 participants, above the 449-participant average among 13 other Episodic Migraine trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03927144, a Phase 4 study of Episodic Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 621 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
Primary Outcome
A migraine day was defined as any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at least one of the following criteria: 1. ≥2 of the following pain features: * Unilateral * Throbbing * Moderate to severe * Exacerbated with exercise/physical activity 2. ≥1 of the following
Conditions Studied
Interventions
- DRUG AMG334
- DRUG Oral Prophylactic
Study Locations (20)
Connecticut
- Yale Center for Clinical Research - New Haven
- New England Institute for Neurology and Headache - Stamford
Florida
- University of Miami Headache Division - Miami
- Premier Research Institute - West Palm Beach
Illinois
- Diamond Headache Clinic - Chicago
- Robbins Headache Clinic - Riverwoods
Massachusetts
- Medvadis - Watertown
- New England Regional Headache Center, Inc - Worcester
Missouri
- Study Metrix Research - City of Saint Peters
- Mercy Health Research - St Louis
Texas
- Texas Neurology - Dallas
- Texas Institute for Neurological Disorders - Sherman
California
- Stanford Headache Center - Stanford
District of Columbia
- George Washington Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 621 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
What the finished NCT03927144 record still lists
NCT03927144 is an interventional study that assigns participants to a tested intervention. The registered 621 participants enrollment target is mid-sized for trials with a published cap, above the 449-participant average among 13 other Episodic Migraine trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which AMG334 is the first listed.
NCT03927144 names 20 study sites across 14 states, led by Connecticut, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03927144 about?
NCT03927144 is a clinical study titled "Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients". The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
What is the current status of trial NCT03927144?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 621 participants. The study started on 2019-05-15. Estimated completion is 2022-09-30.
What conditions does trial NCT03927144 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT03927144?
The interventions under investigation include: AMG334 (DRUG), Oral Prophylactic (DRUG).
Who is sponsoring clinical trial NCT03927144?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03927144 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03927144's enrollment target sits among peer trials
621 5th of 13 higher than 9 of 13 other Episodic Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Episodic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
COMPLETED · Phase 4
-
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
COMPLETED · Phase 4
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
RECRUITING · Phase 3
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RECRUITING · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712355 · 621 participants · Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI